 |
 | Vissza |
Lajkó Eszter; Tuka Bernadett; Fülöp Ferenc; Krizbai István Adorján; Toldi József; Magyar Kálmán; Vécsei László; Kőhidai László:
Kynurenic acid and its derivatives are able to modulate the adhesion and locomotion of brain endothelial cells.
JOURNAL OF NEURAL TRANSMISSION, 125 (6).
pp. 899-912.
ISSN 0300-9564
(2018)
Szökő Éva; Tábi Tamás; Riederer Peter; Vécsei László; Magyar Kálmán:
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease.
JOURNAL OF NEURAL TRANSMISSION, 125 (11).
pp. 1735-1749.
ISSN 0300-9564
(2018)
Tábi Tamás; Szökő Éva; Vécsei László; Magyar Kálmán:
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson’s disease.
Expert Opinion on Drug Metabolism and Toxicology, 9 (5).
pp. 629-636.
ISSN 1742-5255
(2013)
Gulyás Balázs; Pavlova Elena; Kása Péter; Gulya Károly; Bakota Lidia; Várszegi Szilvia; Keller Éva; Horváth Mónika Csilla; Nag Sangram; Hermecz Istvá; Magyar Kálmán; Halldin Christer:
Activated MAO-B in the brain of Alzheimer patients, demonstrated by
[11C]-L-deprenyl using whole hemisphere autoradiography.
Neurochemistry International, 58 (1).
pp. 60-68.
ISSN 0197-0186
(2011)
Hollán Zsuzsa; Vécsei László; Magyar Kálmán:
Adverse effects of dopamine potentiation by long-term treatment with selegiline.
MOVEMENT DISORDERS, 19 (1).
pp. 107-109.
ISSN 0885-3185
(2004)
